teaser
Patient contributions to benefit-risk decisions and the transparency of the process were discussed at the recent joint meeting of The Organisation for Professionals in Regulatory Affairs (TOPRA) and the European Medicines Agency (EMA).
The annual meeting took place in the EMA building in Canary Wharf, London, from November 24
